ABSTRACT Fifty-three (3.6%; actuarially 4.1% at 48 months) of 1465 consecutive in-hospital survivors of valve replacement from 1975 to July 1979 (aortic, mitral, or aortic and mitral, only one untraced) developed prosthetic valve endocarditis (PVE). Incremental risk factors for developing PVE were native valve endocarditis (p < .0001), black race (p = .0001), mechanical prosthesis (vs bioprosthesis) (p = .005), male sex (p = .04), and longer cardiopulmonary bypass time (p = .09). In general, the hazard function for developing PVE was greatest at 3 weeks after valve replacement. Patients with native valve endocarditis had a tendency to develop PVE early after valve replacement, as did patients in whom mechanical prostheses were used. PVE associated with Staphylococcus epidermidis tended to appear within 6 months of valve replacement, whereas streptococcal PVE tended to appear later after valve replacement. PVE took an atypical form in some patients, but patients with possible PVE (n = 6) had the same findings as those with certain PVE (n = 47). In 11 patients bacteriologic confirmation of PVE was not obtained. The typical prosthetic and periprosthetic characteristics of PVE were present in 30 of the 40 cases in which observations were possible. PVE is a serious condition; 34 (64%) of our 53 patients died. Most deaths occurred within 3 months of the first evidence of PVE. Recovery of some patients is possible with appropriate medical and surgical treatment, but more intense preventive measures are indicated.
performed in 1533 patients from January 1, 1975 , to July 1, 1979 . The study group consisted of the 1465 hospital survivors, 818 of whom had undergone isolated aortic valve replacement, 452 of whom had undergone isolated mitral valve replacement, and 195 of whom had undergone concomitant aortic and mitral valve replacement (three of these also having tricuspid valve replacement). Valve replacement was accompanied by coronary artery bypass grafting in 385 patients and in 117 patients by other procedures such as repair of ascending aortic aneurysm, left ventricular aneurysmectomy, reconstruction of ventricular outflow obstruction, or tricuspid annuloplasty. Mechanical prostheses (Bjork-Shiley or Starr-Edwards) were used in 1036 patients, and bioprostheses (Hancock or Carpentier-Edwards types) were used in 429.
All patients received antimicrobial agents for a period (4 to 10 days) after operation. Different protocols were used because of surgeon-to-surgeon differences, patients' drug allergies, and changing ideas as to optimal prophylaxis. Commonly used protocols included nafcillin alone for 2 or 3 postoperative days and oral cephalexin for 4 to 7 more days, nafcillin followed by oral cephradine or cloxacillin, and intravenous cephapirin as the only drug.
Dicumarol was started on the second postoperative day and use continued for only 6 to 12 weeks in most patients with bioprostheses. However, dicumarol was prescribed in a lifelong regimen in all patients with mechanical prostheses.
Definitions. Each patient was classified as having certain PVE, possible PVE, or no PVE during the follow-up period. PVE was classified as certain in patients (1) with an illness clinically consistent with infectious endocarditis, positive blood cultures for the same organism in at least two samples, and no apparent source of bacteremia other than the heart; (2) with positive blood cultures as above, and with typical or suggestive findings (see below for definition) at repeat operation or autopsy; (3) with organisms cultured or stained from prosthetic or annular tissue removed at operation or autopsy, regardless of the clinical course, pathologic findings, or the result of blood cultures; or (4) with absent or negative tissue or blood cultures if the clinical presentation and/or pathologic appearance at repeat operation or autopsy were "typical" (one patient, see below for definition). PVE was classified as possible in patients (1) with negative or absent tissue blood or cultures but with a suggestive clinical presentation or suggestive findings at repeat operation or autopsy or (2) with positive blood cultures and dehiscence of the valve replacement device but with another possible source of bacteremia and neither typical nor suggestive findings in the replacement device at reoperation or autopsy. In the absence of any of these, the patient was considered to have no PVE.
The clinical presentation was considered to be "typical" for PVE in the presence of fever, splenomegaly, peripheral skin or mucocutaneous lesions, and a new regurgitant murmur. The clinical presentation of fever and chills without the above, occurring more than 3 weeks after operation, with or without a new murmur, and without another obvious source of infection was considered to be suggestive of PVE.
Findings at repeat operation or autopsy were considered typical pathologically of PVE if there was an inflammatory reaction with necrotic annular tissue, vegetations, abscesses, or fistulas. Pathologic findings were considered suggestive of PVE when granulation tissue and exudates were on the prosthesis or when there were annular cavities without obvious infection.
Antecedent native valve endocarditis (NVE). Each of the 1465 patients was classified as having certainly active, possibly active, inactive, or no preoperative NVE. NVE was considered to be active in patients (1) with positive blood cultures within 10 days before surgery and with compatible surgical findings, such as vegetations, perforated or destroyed valve leaflets, or ruptured chordae; (2) with organisms cultured or stained from excised native valvular tissue; or (3) with histopathologic evidence of acute infection in excised valvular tissue. NVE was considered to be possibly active in patients with positive blood cultures or with a clinical presentation typical of endocarditis (see earlier criteria) 11 to 42 days before the operation and with compatible surgical findings. NVE was considered to have been present but now inactive in patients (I) with bacteremia or a clinical presentation typical of NVE more than 6 weeks before the operation or (2) with surgical findings typical of healed NVE, including leaflet perforations, destruction of leaflet tissue, or healed vegetations on the leaflets.
Data. The hospital records, including the surgical descriptions of the pathologic appearance, autopsy findings, clinic records of follow-up examinations, and the detailed bacteriologic records from the Division of Infectious Diseases of the Department of Medicine, were reviewed in detail for each patient. The bacteriologic analysis of blood cultures and operative and postmortem specimens was performed as previously detailed.20
As the previous publication indicated, particular precautions were taken to eliminate the possibility of Staphylococcus epidermidis being a contaminant; further, similar findings in three institutions make this possibility unlikely.20
Only one of 1465 patients was lost to follow-up by personal or telephone contact or through the patient's own physician. The interval between operation and last follow-up ranged from 1.5 to 80 months. Ninety-five percent of the patients were followed up for more than 17 months, 90% for more than 22 months, and 50% for more than 43 months.
Patients without PVE who died late after surgery or who required repeat valve operation for other reasons were considered untraced (censored) for PVE on the date of death or on the date of the valve operation. The period of freedom from PVE was considered to be the interval between the valve replacement operation and the evident date of onset of PVE. The evident date of onset of PVE was defined as the date of (1) 
Results
Incidence. Fifty-three (3.6%) of 1465 patients undergoing valve replacement developed certain (n = 47) or possible (n -6) PVE within the follow-up period. The incidence was no different in patients with aortic, mitral, or combined aortic-mitral replacement (p = .6). The actuarial incidence of certain plus possible PVE was 4.1% at 48 months after the original valve replacement (figure 1).
Incremental risk factors for PVE (table 1) . Preoperative NVE, regardless of activity, increased fivefold the probability of PVE. Black race increased fourfold the risk of PVE. The use of a mechanical prosthesis (rather than a bioprosthesis) increased threefold the risk of PVE. Male sex doubled the risk of PVE. A longer cardiopulmonary bypass time mildly increased the risk of PVE. The incidence of these and other variables in the patients who did (n = 53) and did not (n = 1412) develop PVE is tabulated in Appendix 2. The different preoperative antibiotic regimens were found to be no different (p > .20) as regards the subsequent incidence of PVE.
Time course of the risk of PVE. The hazard function for PVE was greatest at 5 weeks after operation and fell rapidly thereafter (figure 2). Patients with NVE who subsequently developed PVE frequently did so within 6 months of operation, in contrast to the group without NVE ( figure 3, A) . The early peak of the hazard function was significantly (p = .04) higher in patients with NVE ( figure 3, B) . Patients with mechanical prostheses had a higher incidence of PVE (p = .08) in the early months after the original valve replacement operation than did those with bioprostheses (figure 4). Months after Operation hazard function in the early period than did female sex.
The patterns of hazard function in blacks and whites were not dissimilar (all p values > .20). Bacteriology. S. epidermidis was the microorganism most commonly responsible for PVE, and staphylococci in general were the most common group (table 2). Among the eight patients with NVE before the first valve replacement, three of the four with viridanstype streptococci had a different organism involved in their PVE. Among six patients with consecutive episodes of PVE, only one had different organisms involved in the two episodes.
Patients who had PVE associated with S. epidermidis tended to develop this complication within 6 months of the operation (figure 5, A). In contrast, patients with streptococcal infection developed it throughout the follow-up period. Thus the hazard function of PVE associated with S. epidermidis has a high early peak at 6 weeks (figure 5, B), in contrast to the low and constant hazard function of the streptococcal PVE (p = .004). These differences were statistical- Twenty of the 53 patients received no repeat operation, and 14 (70%) pf these died (table 4). Ten of these 14 died too quickly to receive any treatment or within 1 week of initiating medical treatment (six with acute heart failure, three suddenly, and one with a septic embolus). Four other patients died with heart failure 10 to 27 days after the start of medical treatment.
Thirty-three of the 53 patients underwent repeat operation for their PVE ( This study demonstrates the continuing incidence (3.6%) of PVE in an environment committed to prophylactic antibiotic therapy and strict aseptic surgical techniques. The finding that the specific valve replaced was not a risk factor is different than the results of most other reports, which indicate a higher incidence of PVE after aortic valve replacement. 1-5, 8, 9, 13, 19, 26, 27, 29-35 This study strongly supports the idea that NVE, active or inactive, is a strong risk factor for PVE. This has not been stated in previous publications, but a number of articles4' 6, 31, 36 describe experiences compatible with this observation. In this study the microorganism presumed to be the cause of the PVE was not infrequently different from the one isolated earlier as the presumed cause of the NVE. Others have also observed a different organism in the NVE than in the PVE in the same patients.6 36 The explanations for the risk-producing effect of inactive NVE, for the occasionally different organisms involved in the NVE and PVE, and for the occasional finding of unexpected positive cultures and a subsequent course of PVE in valve replacement devices removed for routine indications are probably related but not apparent.
Black race was a risk factor in the Cox analysis. Mechanical valves as well as male sex were also risk factors. These ideas have not been articulated in previous studies, but analysis of the experience of others (refs. 2, 4, 6, 8, 13, 16, 19 risk factor. This is consistent with the general experience in surgery that longer operations are associated with increased risks of infection. Although PVE has long been recognized as a timerelated event, with some cases being described as early and others as late, no analysis has previously been made of the risks of PVE at various times after operation. The present study clearly indicates that the risk (expressed as the hazard function) is greatest at 5 weeks; it then declines to a stable level by about 12 months after operation. However, this pattern was influenced by a number of variables. Thus the presence of NVE and male sex imposed a higher hazard function in the first few months after operation. Of particular interest is the fact that patients with a mechanical prosthesis had a higher risk of PVE in the early months after operation than did those with bioprostheses. Nonstented homograft valves in the aortic position have an extremely low incidence of PVE in the early months after operation (Sir Brian Barratt-Boyes: personal communication). This supports the idea that mechanical prostheses may have a particular tendency toward developing early PVE, presumably from surface contamination occurring at the time of operation (p = .08 vs bioprostheses).
The microorganisms associated with the PVE in this study are similar to those in studies reported by others 24, 7, 8, 12, 19, [29] [30] 33 Others have also noted that in socalled early PVE, S. epidermidis is a frequent cause of the infection. 2A, 7, 8, 12, 19, 29, 30, 33 The present study clearly demonstrates the risk of PVE associated with S. epidermidis to be highest in the early weeks after operation. This and other considerations support the idea that PVE occurring early after surgery is caused by organisms acquired in the operating room or perhaps in the intensive care unit in the first few postoperative days. 1-5, 7, 8-11, 30, 32, 33 Widely variable pathologic changes in the prosthesis and the surrounding tissues were found in the current study. This supports the idea that PVE may take atypical forms and that a relatively normal-appearing prosthesis at repeat operation cannot exclude this diagnosis.
This study confirms the lethality of PVE. However, the recovery of some patients by intense medical treatment, or when indicated by one or more operations, indicates the importance of aggressive treatment of this complication. However, renewed efforts toward obtaining a perfect aseptic environment in the perioperative period and trials of more prolonged antibiotic prophylaxis'4 are indicated.
We appreciate the cooperation of our surgical colleagues, 43 was fitted to the data points of the cumulative hazard function plot, with ordinary least squares, to select the equation that best fit the plot and to obtain initial parameter estimates. A similar process was followed for the late component, although it was found that an equation describing a simple linear increase with time adequately fit the cumulative hazard function.
As regards both incidence of PVE and late death after evidence of PVE, the negative generic model was found to be appropriate to describe the early phase of the risk, with the exponent (designated m in the study by Hazelrig et al.43) set to -1, the so-called hyperlogistic equation:
where , is the total cumulative early risk (translatable into survival (S) by the equation S = -8L), /3 is the time in months when half the early risk takes place and roughly corresponds to the time of peak risk, and v is a shaping parameter for the initial phase of early risk (when large, it permits the hazard function curve to have a slight delay before rising 
